Effect of Oridonin-mediated Hallmark Changes on Inflammatory Pathways in Human Pancreatic Cancer (BxPC-3) Cells

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2014 Oct 31

PMID 25356049

Citations 13

Authors

Ru-Yi Chen

Bin Xu

Su-Feng Chen

Si-Si Chen

Ting Zhang

Jun Ren

Jian Xu

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the effect of oridonin on nuclear transcription factors and to study the relationship between biological behavior and inflammatory factors in human pancreatic cancer (BxPC-3) cells.

Methods: BxPC-3 cells were treated with various concentrations of oridonin, and viability curves were generated to test for inhibitory effects of the drug on cells. The expression of cytokines such as interleukin-1β (IL-1β), IL-6, or IL-33 was detected in BxPC-3 cell supernatants using an enzyme-linked immunosorbent assay (ELISA), and the protein expression of nuclear transcription factors including nuclear factor κB, activating protein-1, signal transducer and activator of transcription 3, bone morphogenetic protein 2, transforming growth factor β1 and sma and mad homologues in BxPC-3 cells was detected using Western blot. Carcinoma hallmark-related proteins such as survivin, vascular endothelial growth factor, and matrix metallopeptidase 2 were also detected using immunoblotting, and intra-nuclear IL-33 expression was detected using immunofluorescent staining.

Results: Treatment with oridonin reduced the viability of BxPC-3 cells in a dose dependent manner. The cells exhibited reduced growth following treatment with 8 μg/mL oridonin (13.05% ± 3.21%, P < 0.01), and the highest inhibitory ratio was 90.64% ± 0.70%, which was achieved with oridonin at a dose of 32 μg/mL. The IC50 value of oridonin in BxPC-3 cells was 19.32 μg/mL. ELISA analysis revealed that oridonin down-regulated the inflammatory factors IL-1β, IL-6, and IL-33 in a dose-dependent manner. IL-1β expression was significantly reduced in the 16 and 32 μg/mL treatment groups compared to the control group (12.97 ± 0.45 pg/mL, 11.17 ± 0.63 pg/mL vs 14.40 ± 0.38 pg/mL, P < 0.01). Similar trends were observed for IL-6 expression, which was significantly reduced in the 16 and 32 μg/mL treatment groups compared to the control group (4.05 ± 0.14 pg/mL vs 4.45 ± 0.43 pg/mL, P < 0.05; 3.95 ± 0.13 pg/mL vs 4.45 ± 0.43 pg/mL, P < 0.01). IL-33 expression was significantly reduced in the 8, 16, and 32 μg/mL treatment groups compared to the control group (911.05 ± 14.18 pg/mL vs 945.25 ± 12.09 pg/mL, P < 0.05; 802.70 ± 11.88 pg/mL, 768.54 ± 10.98 pg/mL vs 945.25 ± 12.09 pg/mL, P < 0.01). Western blot and immunofluorescent staining analyses suggested that oridonin changed the hallmarks and regulated the expression of various nuclear transcription factors.

Conclusion: The results obtained suggest that oridonin alters the hallmarks of pancreatic cancer cells through the regulation of nuclear transcription factors.

Citing Articles

Oridonin from : An emerging potential in cancer therapy - A comprehensive review.

Ali M, Khan N, Ali A, Akram H, Zafar N, Imran K Food Sci Nutr. 2024; 12(5):3046-3067.

PMID: 38726411 PMC: 11077219. DOI: 10.1002/fsn3.3986.

Advances in the treatment of pancreatic cancer with traditional Chinese medicine.

Zhang Y, Xu H, Li Y, Sun Y, Peng X Front Pharmacol. 2023; 14:1089245.

PMID: 37608897 PMC: 10440824. DOI: 10.3389/fphar.2023.1089245.

Oridonin Attenuates Burkholderia cenocepacia Virulence by Suppressing Quorum-Sensing Signaling.

Li X, Wang K, Wang G, Cui B, Song S, Sun X Microbiol Spectr. 2022; 10(4):e0178722.

PMID: 35856676 PMC: 9430380. DOI: 10.1128/spectrum.01787-22.

Oridonin Dose-Dependently Modulates the Cell Senescence and Apoptosis of Gastric Cancer Cells.

Wang Y, Lv H, Dai C, Wang X, Yin Y, Chen Z Evid Based Complement Alternat Med. 2021; 2021:5023536.

PMID: 34795783 PMC: 8595004. DOI: 10.1155/2021/5023536.

Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.

Bose S, Banerjee S, Mondal A, Chakraborty U, Pumarol J, Croley C Cells. 2020; 9(6).

PMID: 32545187 PMC: 7348822. DOI: 10.3390/cells9061451.

References

Liptay S, Weber C, Ludwig L, Wagner M, Adler G, Schmid R . Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer. 2003; 105(6):735-46. DOI: 10.1002/ijc.11081. View

Kleeff J, Maruyama H, Friess H, Buchler M, Falb D, Korc M . Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun. 1999; 255(2):268-73. DOI: 10.1006/bbrc.1999.0171. View

Ungefroren H, Groth S, Sebens S, Lehnert H, Gieseler F, Fandrich F . Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer. 2011; 10:67. PMC: 3112431. DOI: 10.1186/1476-4598-10-67. View

Rogers A, Smith M, Doolan P, Clarke C, Clynes M, Murphy J . Invasive markers identified by gene expression profiling in pancreatic cancer. Pancreatology. 2012; 12(2):130-40. DOI: 10.1016/j.pan.2011.12.011. View

Hutzen B, Willis W, Jones S, Cen L, DeAngelis S, Fuh B . Dietary agent, benzyl isothiocyanate inhibits signal transducer and activator of transcription 3 phosphorylation and collaborates with sulforaphane in the growth suppression of PANC-1 cancer cells. Cancer Cell Int. 2009; 9:24. PMC: 3224892. DOI: 10.1186/1475-2867-9-24. View

Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D . Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta. 2013; 1845(1):42-52. DOI: 10.1016/j.bbcan.2013.11.003. View

Shaulian E, Karin M . AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002; 4(5):E131-6. DOI: 10.1038/ncb0502-e131. View

Chen S, Nieh S, Jao S, Wu M, Liu C, Chang Y . The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol. 2013; 231(2):180-9. DOI: 10.1002/path.4226. View

Jin X, Wu Y . Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/Smad signaling. Anat Rec (Hoboken). 2014; 297(5):802-9. DOI: 10.1002/ar.22897. View

10.

Li D, Xie K, Wolff R, Abbruzzese J . Pancreatic cancer. Lancet. 2004; 363(9414):1049-57. DOI: 10.1016/S0140-6736(04)15841-8. View

11.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

12.

Roussel L, Erard M, Cayrol C, Girard J . Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep. 2008; 9(10):1006-12. PMC: 2572127. DOI: 10.1038/embor.2008.145. View

13.

Rebours V, Boutron-Ruault M, Schnee M, Ferec C, Maire F, Hammel P . Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008; 103(1):111-9. DOI: 10.1111/j.1572-0241.2007.01597.x. View

14.

Xiong H, Abbruzzese J, Lin E, Wang L, Zheng L, Xie K . NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer. 2003; 108(2):181-8. DOI: 10.1002/ijc.11562. View

15.

Choi Y, Park J, Kim J, Rho S, Park H, Kim Y . Nuclear IL-33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation. Biochem Biophys Res Commun. 2012; 421(2):305-11. DOI: 10.1016/j.bbrc.2012.04.005. View

16.

Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler M . The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene. 1999; 18(39):5363-72. DOI: 10.1038/sj.onc.1202909. View

17.

Schmieder A, Multhoff G, Radons J . Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. Cytokine. 2012; 60(2):514-21. DOI: 10.1016/j.cyto.2012.06.286. View

18.

Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y . Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci. 2011; 56(12):3596-601. DOI: 10.1007/s10620-011-1760-5. View

19.

Zhao S, VenkataSubbaRao K, Lazor J, Sperry J, Jin C, Cao L . Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res. 2008; 68(11):4221-8. DOI: 10.1158/0008-5472.CAN-07-5123. View

20.

Jones S, Zhang X, Parsons D, Cheng-Ho Lin J, Leary R, Angenendt P . Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897):1801-6. PMC: 2848990. DOI: 10.1126/science.1164368. View